Pfizer
Donald Trump thanks Novartis for halting price hikes
July 20, 2018Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes
Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …
Novartis follows Pfizer’s lead, pledges no price hikes in 2018
July 18, 2018Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
Top Ten most popular articles on Pharmafile.com this week
July 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10
In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the …
Pfizer restructures in preparation for potential sell off
July 12, 2018Sales and Marketing Pfizer, bisoimilar, consumer, health
Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from …
Trump forces Pfizer to back down and delay price hikes until 2019
July 11, 2018Research and Development, Sales and Marketing Alex Azar, Donald Trump, Ian Read, Pfizer, President trump, Trump, druig pricing, pharma
Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the …
Syntimmune appoints Pfizer, AbbVie veteran as new CMO
July 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune
The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …
Trump slams Pfizer over price hikes, Pfizer responds
July 10, 2018Manufacturing and Production, Sales and Marketing Donald Trump, Drug pricing, Pfizer, Trump, pharma
Price hiking in the pharmaceutical industry continues to persist, and has become ever more prominent in the public sphere thanks …
Top Ten most popular articles on Pharmafile.com this week
July 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Astrazenaca, Donald Trump, Pfizer, pharma, top ten
As the first week of July comes to an end we take a look over the most popular stories of …
Unfazed by Trump, Pfizer hikes prices for 100 of its drugs
July 3, 2018Manufacturing and Production, Sales and Marketing Pfizer, President trump, Trump, pharma, price hikes
After a campaign full of not-so-veiled threats directed at the pharma industry, and a presidency which has so far failed …
Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis
June 29, 2018Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …
Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori
June 28, 2018Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma
UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma
Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …
Pfizer successfully appeals 2,600% price hiking case
June 8, 2018Medical Communications Flynn Pharma, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer and co-defendant Flynn Pharma have won their appeal against a £90 million fine imposed on them by the Competition …
Pfizer pumps $600m into venture fund, targeting neuroscience
June 7, 2018Research and Development, Sales and Marketing Pfizer, biotech, drugs, neuroscience, pharma, pharmaceutical
Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
